Stomach and Small Bowel Diseases and Disorders

Featured Article
Triple therapy has been the gold standard for treatment of H pylori infection for several years. New research casts light on whether that standard should change.
Jennifer is a 27-year-old patient with Celiac disease who gave birth to her first child several months earlier. She asks if she should be worried about her child also developing the disease, and if she should keep the child gluten-free as it gets older.
The authors of a new study sought to determine whether H pylori eradication treatment reduces the risk of gastric cancer among those with a family history of gastric cancer in first-degree relatives.
Which psychological intervention do you most often recommend to patients with eosinophilic gastrointestinal tract disorders seen in your practice? Let us know by taking our poll!
Do you know the potential complications of superior mesenteric artery syndrome? Take our short pop quiz to find out!
Do you know when an individual with celiac disease is at greater risk of developing another autoimmune disorder? Take our pop quiz to find out.
Take our pop quiz to find out when the first case of Rapunzel syndrome was described.
Because the treatment options for eosinophilic gastrointestinal disorders are limited, authors of the ENIGMA study evaluated whether the AK002 antibody could be a therapy option in eosinophilic gastritis and gastroenteritis. The results of the phase 2 clinical trial were presented at the ACG 2019 Annual Meeting.
In a new study, researchers assessed the incidence of autoimmune disorders among more than 200 patients who had received treatment for celiac disease.
Previous research has suggested an association between H pylori infection and the incidence of ITP.
Current Helicobacter pylori is known to be associated with cardiovascular disease in patients with a history of CVD, but could this risk also be present among individuals without history of CVD? In a new study of nearly 500 patients, researchers aimed to answer this question.